WO2018196823A1 - 2-amino-quinoline derivatives - Google Patents
2-amino-quinoline derivatives Download PDFInfo
- Publication number
- WO2018196823A1 WO2018196823A1 PCT/CN2018/084674 CN2018084674W WO2018196823A1 WO 2018196823 A1 WO2018196823 A1 WO 2018196823A1 CN 2018084674 W CN2018084674 W CN 2018084674W WO 2018196823 A1 WO2018196823 A1 WO 2018196823A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- quinolin
- optionally substituted
- salt
- ethoxymethyl
- imidazo
- Prior art date
Links
- 0 *NC(C1N**(**2)C11)=NC3=C1C2=Br*=*3 Chemical compound *NC(C1N**(**2)C11)=NC3=C1C2=Br*=*3 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Definitions
- the present invention relates to 2-amino-quinoline derivatives, such as imidazoquinoline and pyrazoloquinoline analogs as agonists of toll-like receptors 7 and 8 (TLR7 and TLR8) , as well as pharmaceutical compositions comprising the same.
- the present invention also relates to the use of the compounds, compositions, and the method of activating TLR7 and TLR8 in treating various diseases.
- TLR7 and TLR8 are toll-like receptors 7 and 8 respectively, and they lie in close proximity to each other on the human X chromosome. Both TLR7 and TLR8 recognize single-stranded RNA of viruses such as HIV and HCV. TLR7 has been shown to play a significant role in the pathogenesis of autoimmune disorders such as Systemic Lupus Erythematosus (SLE) as well as in the regulation of antiviral immunity. Genetic variants in TLR8 have recently been linked to susceptibility to pulmonary tuberculosis. TLR7 is functional both in human and mouse, while TLR8 is only functional in human, but it seems to counteract TLR7 activity.
- SLE Systemic Lupus Erythematosus
- TLR7/8 agonists as immune response enhancers are their simultaneous stimulation of several cell types.
- TLR7 and TLR8 are expressed mostly on immune cells such as antigen presenting cells, including plasmacytoid dendritic cells (pDC) and myeloid dendritic cells (mDC) , as well as natural killer cells, and macrophages.
- pDC plasmacytoid dendritic cells
- mDC myeloid dendritic cells
- Activation of TLR7/8 on pDCs and mDCs results in the induction and release of type I interferons (IFN) , tumor necrosis factor alpha (TNF ⁇ ) , and interleukin 12 (IL-12) , which is an important step for the initiation of innate and adaptive immunities to kill cancer cells.
- IFN interferons
- TNF ⁇ tumor necrosis factor alpha
- IL-12 interleukin 12
- TLR7 and TLR8 Small molecule agonists at TLR7 and TLR8 have increased interest in both antiviral and cancer research own to their profound antiviral and antitumor activity.
- the lead compound of the imidazoquinoline family, imiquimod is efficacious against many primary skin tumors and cutaneous metastases and is marketed as a topical formulation.
- Resiquimod (R-848) from the same imidazoquinoline family, is a low molecular weight synthetic molecule that activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway. It acts as an immune response modifier and has antiviral and antitumor activity. It has several mechanisms of action, being both an agonist for toll-like receptors 7 and 8, and an upregulator of the opioid growth factor receptor.
- R-848 is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, as an adjuvant to increase the effectiveness of vaccines, and as an adjuvant to immunotherapy in allergic rhinitis (AR) patient. Therefore, in addition to their use as stand-alone immunotherapeutic agent, TLR7/8 agonists hold promise as adjuvants in cancer vaccine or adoptive T cell transfer protocols. Extension of the families of the known synthetic TLR7/8 agonists, such as described above, pave the way to the development and identification of TLR7/8 agonists that are well tolerated, more selective with potent antitumor and antiviral activity, broadly applicable, and more effective as adjuvants.
- 2-amino-quinoline derivatives Described herein are 2-amino-quinoline derivatives, pharmaceutically acceptable salts, solvates, prodrug and active metabolites, that are agonists of toll-like receptors 7 and 8 (TLR7/8) .
- These compounds may be used to treat viral infection, such as HCV, cancer, and allergic diseases in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.
- Some embodiments include a compound represented by Formula 1:
- a dashed line represents the presence or absence of a bond
- a 1 is CR 1 , NR 1A , or N
- a 2 is CR 2 , NR 2A , O, or S
- B 1 is CR 5 or N
- B 2 is CR 6 or N
- B 3 is CR 7 or N
- R 1 and R 2 are independently F, Cl, Br, I, NO 2 , CN, R a , -OR a , -NR a R b , -NHCOR a , -NHSO 2 R a , -OCOR a , or -SO 2 R a
- X is a bond, O, NR a , -CO-, -SO-, or -SO 2 -, -CONR a , hydrocarbyl
- R 3 is H or C 1-30 organyl
- X-R 3 is F or Cl
- Some embodiments include a pharmaceutical dosage form comprising a subject compound.
- a subject compound or a subject composition may be used for activating TLR7/8.
- a subject compound or composition may be used as adjuvants in cancer vaccine or adoptive T cell transfer protocols.
- Some embodiments include a method of treating a disease or disorder associated with a TLR7/8 agonist comprising administering an effective amount of a subject compound to a mammal in need thereof.
- Some embodiments include use of a subject compound in the manufacture of a medicament for the treatment of a disease or disorder associated with a TLR7/8 agonist.
- a compound or chemical structural feature such as alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.
- substituted has the broadest meaning known to one of ordinary skill in the art, and includes a moiety that occupies a position normally occupied by one or more hydrogen atoms attached to a parent compound or structural feature.
- a substituent may be an ordinary organic moiety known in the art, which may have a molecular weight (e.g. the sum of the atomic masses of the atoms of the substituent) of 15-50 g/mol, 15-100 g/mol, 15-150 g/mol, 15-200 g/mol, 15-300 g/mol, or 15-500 g/mol.
- a molecular weight e.g. the sum of the atomic masses of the atoms of the substituent
- a substituent comprises, or consists of: 0-30, 0-20, 0-10, or 0-5 carbon atoms; and 0-30, 0-20, 0-10, or 0-5 heteroatoms, wherein each heteroatom may independently be: N, O, S, Si, F, Cl, Br, or I; provided that the substituent includes one C, N, O, S, Si, F, Cl, Br, or I atom.
- substituents include, but are not limited to, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, acyl, acyloxy, alkylcarboxylate, thiol, alkylthio, cyano, halo, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxyl, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, etc
- molecular weight is used with respect to a moiety or part of a molecule to indicate the sum of the atomic masses of the atoms in the moiety or part of a molecule, even though it may not be a complete molecule.
- alkyl has the broadest meaning generally understood in the art and may include a moiety composed of carbon and hydrogen containing no double or triple bonds.
- Alkyl may be linear alkyl, branched alkyl, cycloalkyl, or a combination thereof and in some embodiments, may contain from one to thirty-five carbon atoms.
- alkyl may include C 1-10 linear alkyl, such as methyl (-CH 3 ) , methylene (-CH 2 -) , ethyl (-CH 2 CH 3 ) , ethylene (-C 2 H 4 -) , propylene (-C 3 CH 6 -) , n-butyl (-CH 2 CH 2 CH 2 CH 3 ) , n-pentyl (-CH 2 CH 2 CH 2 CH 2 CH 3 ) , n-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ) , etc.; C 3-10 branched alkyl, such as C 3 H 7 (e.g.
- C 4 H 9 e.g. branched butyl isomers
- C 5 H 11 e.g. branched pentyl isomers
- C 6 H 13 e.g. branched hexyl isomers
- C 7 H 15 e.g. heptyl isomers
- C 3-10 cycloalkyl such as C 3 H 5 (e.g. cyclopropyl)
- C 4 H 7 e.g. cyclobutyl isomers such as cyclobutyl, methylcyclopropyl, etc.
- C 5 H 9 e.g.
- cyclopentyl isomers such as cyclopentyl, methylcyclobutyl, dimethylcyclopropyl, etc. ) C 6 H 11 (e.g. cyclohexyl isomers) , C 7 H 13 (e.g. cycloheptyl isomers) , etc.; and the like.
- aryl includes a group that can be derived from a monocyclic and polycyclic aromatic hydrocarbon by removal of a hydrogen atom from a ring carbon atom.
- the “aryl” may include an aromatic ring or aromatic ring system such as phenyl, naphthyl, etc.
- heteroaryl has the broadest meaning understood by a person of ordinary skill in the art and includes an “aryl” which has one or more heteroatoms in the ring or ring system, such as pyridinyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, oxadiazolyl, isoxazolyl, indolyl, quinolinyl, benzofuranyl, benzothienyl, benzooxazolyl, benzothiazolyl, benzoimidazolyl, etc.
- any reference to a compound herein by structure, name, or any other means includes pharmaceutically acceptable salts, such as HCl, HBr, HI, H 2 SO 4 , acetate, citrate, phosphate, sodium, potassium, and ammonium salts; prodrugs, such as ester prodrugs; alternate solid forms, such as polymorphs, solvates, hydrates, etc.; tautomers; or any other chemical species that may rapidly convert to a compound described herein under conditions in which the compounds are used as described.
- pharmaceutically acceptable salts such as HCl, HBr, HI, H 2 SO 4 , acetate, citrate, phosphate, sodium, potassium, and ammonium salts
- prodrugs such as ester prodrugs
- alternate solid forms such as polymorphs, solvates, hydrates, etc.
- tautomers or any other chemical species that may rapidly convert to a compound described herein under conditions in which the compounds are used as described.
- a name or structural representation includes any stereoisomer or any mixture of stereoisomers.
- treat, “treating, “ or “treatment” includes use of a compound, composition, therapeutically active agent, or drug in the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
- a dashed line represents the presence or absence of a bond.
- compounds represented by Formulas 1A and 1B are included.
- a 1 is CR 1 , NR 1A , or N. In some embodiments, A 1 is CR 1 . In some embodiments, A 1 is NR 1A . In some embodiment, A 1 is N.
- a 2 is CR 2 , NR 2A , O, or S.
- a 2 is CR 2 .
- a 2 is NR 2A .
- a 2 is O.
- a 2 is S.
- X is a bond.
- X is O.
- X is NR a .
- X-R 3 is F.
- X-R 3 is Cl.
- R a or R b is independently H or organyl, such as C 1-30 organyl, including any organic substituent group, regardless of functional type, having a free valence at a carbon, such as optionally substituted alkyl, e.g.
- C 1-30 , C 1-12 , C 1-6 , or C 1-3 alkyl including methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, C 6 alkyl, C 7 alkyl, C 8 alkyl, C 9 alkyl, C 10 alkyl, C 11 alkyl, C 12 alkyl, C 13 alkyl, C 14 alkyl, C 15 alkyl, C 16 alkyl, C 17 alkyl, C 18 alkyl, C 19 alkyl, C 20 alkyl, C 21 alkyl, C 22 alkyl, C 23 alkyl, C 24 alkyl, C 25 alkyl, C 26 alkyl, C 27 alkyl, C 28 alkyl, C 29 alkyl, C 30 alkyl, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl, C 6 cycloalkyl, C 7 cycloalkyl, C 8 cyclo
- alkenyl including ethenyl, C 3 alkenyl, C 4 alkenyl, C 5 alkenyl, C 6 alkenyl, C 7 alkenyl, C 8 alkenyl, C 9 alkenyl, C 10 alkenyl, C 11 alkenyl, C 12 alkenyl, C 4 cycloalkenyl, C 5 cycloalkenyl, C 6 cycloalkenyl, C 7 cycloalkenyl, C 8 cycloalkenyl, C 9 cycloalkenyl, C 10 cycloalkenyl, C 11 cycloalkenyl, C 12 cycloalkenyl, etc.; optionally substituted alkynyl, e.g.
- C 2-12 or C 2-6 alkynyl including ethynyl, C 3 alkynyl, C 4 alkynyl, C 5 alkynyl, C 6 alkynyl, C 7 alkynyl, C 8 alkynyl, C 9 alkynyl, C 10 alkynyl, C 11 alkynyl, C 12 alkynyl, C 5 cycloalkynyl, C 6 cycloalkynyl, C 7 cycloalkynyl, C 8 cycloalkynyl, C 9 cycloalkynyl, C 10 cycloalkynyl, C 11 cycloalkynyl, C 12 cycloalkynyl, etc.; optionally substituted aryl, such as optionally substituted phenyl, optionally substituted naphthyl, etc.; optionally substituted heterocyclyl, optionally substituted heteroaryl, etc.; organyl also includes ethyn
- R a or R b is independently H or C 1-30 hydrocarbyl, such as alkyl, alkenyl, alkynyl, or phenyl.
- C 1-30 organyl can be substituted by halogen, hydroxyl, amines, alkoxyl, aryl, heteroaryl, sulfone, sulfonamide, carboxylic acid, amide, reversed amide, ester, cycloalkyl, heterocycloalkyl, carbonyl, alkyl, alkenyl, alkynyl, phosphonamidic acid, phosphinic amide, or phosphine oxide.
- Some embodiments include a compound of Formula 2 or Formula 2A.
- B 1 is CR 5 or N. In some embodiments, B 1 is CR 5 . In some embodiments, B 1 is N.
- B 2 is CR 6 or N. In some embodiments, B 2 is CR 6 . In some embodiments, B 2 is N.
- B 3 is CR 7 or N. In some embodiments, B 3 is CR 7 . In some embodiments, B 3 is N.
- Some embodiments include a compound of Formula 3A, 3B, 3C, 3D, 3E, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13.
- R 1 or R 1A is independently H or any substituent, such as F, Cl, Br, I, NO 2 , CN, R a , -OR a , -NR a R b , -NHCOR a , -NHSO 2 R a , -OCOR a , or -SO 2 R a .
- R 1 or R 1A is C r H 2r+1 O, wherein r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, including C 2 H 5 O, such as - (CH 2 ) 2 OH; C 3 H 7 O, such as -CH 2 OCH 2 CH 3 , - (CH 2 ) 2 OCH 3 , etc.; C 1-12 alkyl, such as - (CH 2 ) 3 CH 3, -CH 2 CH 2 CH (CH 3 ) 2 .
- R 1 or R 1A is - (CH 2 ) 2 OH. In some embodiments, R 1 or R 1A is -CH 2 OCH 2 CH 3 . In some embodiments, R 1 or R 1A is - (CH 2 ) 2 OCH 3 . In some embodiments, R 1 or R 1A is - (CH 2 ) 3 CH 3 . In some embodiments, R 1 or R 1A is -CH 2 CH 2 CH (CH 3 ) 2 .
- R 2 or R 2A is independently H or any substituent, such as -CH 3 , -CH 2 CH (CH 3 ) 2 , -CH 2 C (CH 3 ) 2 R 8 , -CH 2 CH 2 C (CH 3 ) 2 R 8 , -C 4 H 9 O, -CH 2 CH 2 OCH (CH 3 ) 2 .
- R 2 or R 2A is H. In some embodiments, R 2 or R 2A is CH 3 . In some embodiments, R 2 or R 2A is -CH 2 CH (CH 3 ) 2 . In some embodiments, R 2 or R 2A is -CH 2 C (CH 3 ) 2 R 8 . In some embodiments, R 2 or R 2A is -CH 2 C (CH 3 ) 2 OH. In some embodiments, R 2 or R 2A is -CH 2 CH 2 C (CH 3 ) 2 OH. In some embodiments, R 2 or R 2A is -CH 2 CH 2 OCH (CH 3 ) 2 .
- R 3 is any substituent, such as C 1-30 optionally substituted alkyl, -C w H 2w+1 O or an ester thereof, wherein w is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; - (C u H 2u O 0-1 ) -Z- (C v H 2v+1 ) , wherein Z is a bond, O, NHSO 2 , or NHCO, u is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and v is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24; or - (C t H 2t O 0-1 ) -Ht, wherein t is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and Ht is optionally substituted C 3-10 heterocyclyl
- R 3 is H. In some embodiment, R 3 is CH 3 . In some embodiments, R 3 is -CH 2 CH (CH 3 ) 2. In some embodiments, R 3 is - (CH 2 ) 2 CH (CH 3 ) 2. In some embodiments, R 3 is -CH 2 CH (OH) CH 3. In some embodiments, R 3 is - (CH 2 ) 2 CH (OH) CH 3 . In some embodiments, R 3 is - (CH 2 ) 2 C (CH 3 ) 2 OH.
- R 3 is (CH 2 ) 2 OCH (CH 3 ) 2 , - (CH 2 ) 3 NHSO 2 CH 3 , - (CH 2 ) 4 NHSO 2 CH 3 , - (CH 2 ) 2 O (CH 2 ) 2 NHSO 2 CH 3 , - (CH 2 ) 3 NHCOC 17 H 35 , - (CH 2 ) 3 NHCOCH 3 , - (CH 2 ) 4 NHCOCH 3 , - (CH 2 ) 4 NHCOC 17 H 35 , - (CH 2 ) 3 NH 2 ,
- R 3 is C 1-3 alkyl optionally substituted with 1 to 6 of R 8A , same or different, wherein R 8A is OH, oxide, C 1-6 organyl, or -O- (C 1-6 organyl) .
- R 4 is H or any substituent, such as hydrocarbyl.
- R 4 is H.
- R 5 is H or any substituent, such as F, Cl, R a , -CO 2 R a , -CONR a R b , CN, -OR a , -NR a R b , -NHCOR a , -NHSO 2 R a , -OCOR a , or -SO 2 R a , wherein R a and R b are independently H or C 1-30 organyl.
- R 5 is - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , wherein Z is a bond, O, -NHSO 2 , or -NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6.7.8.9.10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24.
- R 5 is H.
- R 6 is H or any substituent, such as F, Cl, R a , -CO 2 R a , -CONR a R b , CN, -OR a , -NR a R b , -NHCOR a , -NHSO 2 R a , -OCOR a , or -SO 2 R a , wherein R a and R b are independently H or C 1-30 organyl.
- R 6 is - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , wherein Z is a bond, O, -NHSO 2 , or -NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24. In some embodiments, R 6 is H.
- R 7 is H or any substituent, such as F, Cl, R a , -CO 2 R a , -CONR a R b , CN, -OR a , -NR a R b , -NHCOR a , -NHSO 2 R a , -OCOR a , or -SO 2 R a , wherein R a and R b are independently H or C 1-30 organyl.
- R 7 is - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , wherein Z is a bond, O, -NHSO 2 , or -NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24. In some embodiments, R 7 is H.
- R 8 is H, OH or C 1-6 alkyl. In some embodiments, R 8 is H. In some embodiments, R 8 is OH. In some embodiment, R 8 is CH 3 .
- R 8A is OH, oxide, C 1-6 organyl, or -O- (C 1-6 organyl) . 1 to 6, same or different R 8A can be attached at any ring C-atom.
- R 8A is OH.
- R 8A is CH 3 .
- two different R 8A such as CH 3 and OH, are attached to a same ring C-atom.
- R 8A is -C (CH 3 ) 2 OH.
- R 3 and R 4 are independently H or C 1-12 organyl;
- R 1 , R 2 , R 5 , R 6 , and R 7 are independently F, Cl, Br, I, NO 2 , CN, -OR a , -NR a R b , -OCOR a , or -SO 2 R a ;
- R 1A and R 2A are R a ;
- R a and R b are independently H or C 1-12 organyl;
- R 8 is H or OH.
- R 5 and R 6 or R 6 and R 7 can be optionally linked to form a saturated or an unsaturated ring.
- Some embodiments include optionally substituted 9-methoxy-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof.
- Some embodiments include optionally substituted 1- (4-amino-2- (ethoxymethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -1-isobutyl-9-methoxy-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 1- (4-amino-9-methoxy-2- (2-methoxyethyl) -1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 1- (4-amino-2- (2-hydroxyethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 4- ( (4-amino-2- (ethoxymethyl)
- Some embodiments include optionally substituted 4-amino-2H-pyrazolo [3, 4-c] quinolin-9-ol or a salt thereof; or optionally substituted 4-amino-2-isopentyl-2H-pyrazolo [3, 4-c] quinolin-9-ol or a salt thereof; optionally substituted 2-isopentyl-9- (isopentyloxy) -2H-pyrazolo [3, 4-c] quinolin-4-amine or a salt thereof; or optionally substituted 2-butyl-9- (isopentyloxy) -2H-pyrazolo [3, 4-c] quinolin-4-amine or a salt thereof.
- Embodiment 1 A compound represented by a formula:
- a 1 is CR 1 , NR 1A , or N;
- a 2 is CR 2 , NR 2A , O, or S;
- B 1 is CR 5 or N
- B 2 is CR 6 or N
- B 3 is CR 7 or N
- R 1 and R 2 are independently F, Cl, Br, I, NO 2 , CN, R a , -OR a , -NR a R b , -NHCOR a , -NHSO 2 R a , -OCOR a , or -SO 2 R a ;
- X is a bond, O, NR a , -CO-, -SO-, or -SO 2 -, -CONR a , hydrocarbyl, and R 3 is H or C 1-30 organyl; or X-R 3 is F or Cl;
- R 1A , R 2A , R 4 , R a , and R b are independently H or C 1-30 organyl;
- R 5 , R 6 , and R 7 are independently F, Cl, Br, I, NO 2 , CN, R a , -OR a , -NR a R b , -NHCOR a , -NHSO 2 R a , -OCOR a , -SO 2 R a , or -X 1 - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , wherein R 5 and R 6 or R 6 and R 7 can be optionally linked to form a ring;
- X 1 is a bond, O, NR a , -CO-, -SO-, or -SO 2 -;
- Z is a bond, O, NHSO 2 , or NHCO;
- n 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
- n 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- Embodiment 2 The compound of embodiment 1, further represented by a formula:
- R 3 is C 1-30 organyl.
- R 3 is C 1-3 alkyl optionally substituted with 1 to 6 R 8A groups, wherein each R 8A group is independently OH, oxide, C 1-6 organyl, or -O- (C 1-6 organyl) .
- Embodiment 3 The compound of embodiment 1, further represented by a formula:
- R 4 is H, C 1-30 non-aromatic organyl, or C 1-30 aromatic organyl containing an aromatic group that is not directly attached to the N atom.
- Embodiment 4 The compound of embodiment 1, 2 or 3, wherein R 1 or R 1A is C 1-12 optionally substituted alkyl.
- Embodiment 5 The compound of embodiment 4, wherein R 1 or R 1A is -C r H 2r+1 O, or an ester thereof, wherein r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- Embodiment 6 The compound of embodiment 5, wherein R 1 or R 1A is -C 3 H 7 O.
- Embodiment 7 The compound of embodiment 6, wherein R 1 or R 1A is -CH 2 OCH 2 CH 3 .
- Embodiment 8 The compound of embodiment 1, 2, 3, 4, 5, 6, or 7, wherein R 2 or R 2A is H or C 1- 12 optionally substituted alkyl.
- Embodiment 9 The compound of embodiment 8, wherein R 2 or R 2A is C 1-6 alkyl, or -C y H 2y+1 O or an ester thereof, wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- Embodiment 10 The compound of embodiment 9, wherein R 2 or R 2A is -C 4 H 9 O.
- Embodiment 11 The compound of embodiment 10, wherein R 2 or R 2A is -CH 2 -CH (CH 3 ) 2 -OH.
- Embodiment 12 The compound of embodiment 8, wherein R 2 or R 2A is H.
- Embodiment 13 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, wherein R 3 is C 1-30 optionally substituted alkyl.
- Embodiment 14 The compound of embodiment 13, wherein R 3 is C 1-10 alkyl, or -C w H 2w+1 O or an ester thereof, wherein w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- Embodiment 15 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein R 3 is - (C t H 2t O 0-1 ) -Ht, wherein t is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and Ht is optionally substituted C 3-6 heterocyclyl.
- Embodiment 16 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein R 3 is - (C u H 2u O 0-1 ) -Z- (C v H 2v+1 ) , wherein Z is a bond, O, NHSO 2 , or NHCO, u is 0, 1, 2, 3, 4, 5, or 6, and v is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- Embodiment 17 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13, wherein R 3 is - (C u H 2u O 0-1 ) -NR a R b , and u is 1, 2, 3, 4, 5, or 6, wherein R a and R b are independently H or C 1-6 alkyl.
- Embodiment 18 The compound of embodiment 14, wherein R 3 is C 5 H 11 O.
- Embodiment 19 The compound of embodiment 18, wherein R 3 is -CH 2 -CH 2 -CH (CH 3 ) 2 OH.
- Embodiment 20 The compound of embodiment 17, wherein R 3 is -CH 2 -CH 2 -CH 2 -NH 2 .
- Embodiment 21 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, wherein R 4 is H or C 1-6 alkyl.
- Embodiment 22 The compound of embodiment 21, wherein R 4 is H.
- Embodiment 23 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22, wherein R 5 is R a , F, Cl, -CO 2 R a , -CONR a R b , CN, -OR a , -NR a R b , -OCOR a , or -SO 2 R a , wherein R a and R b are independently H or C 1-6 alkyl.
- Embodiment 24 The compound of embodiment 23, wherein R 5 is H.
- Embodiment 25 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22, wherein R 5 is - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , wherein Z is a bond, O, NHSO 2 , or NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25.
- Embodiment 26 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, wherein R 6 is R a , F, Cl, -CO 2 R a , -CONR a R b , CN, -OR a , -NR a R b , -OCOR a , or -SO 2 R a , wherein R a and R b are independently H or C 1-6 alkyl.
- Embodiment 27 The compound of embodiment 26, wherein R 6 is H.
- Embodiment 28 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25, wherein R 6 is - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , wherein Z is a bond, O, NHSO 2 , or NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- Embodiment 29 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28, wherein R 7 is R a , F, Cl, -CO 2 R a , -CONR a R b , CN, -OR a , -NR a R b , -OCOR a , or -SO 2 R a , wherein R a and R b are independently H or C 1-6 alkyl.
- Embodiment 30 The compound of embodiment 29, wherein R 7 is H.
- Embodiment 31 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
- R 7 is - (C m H 2m O 0-1 ) -Z- (C n H 2n+1 ) , wherein Z is a bond, O, NHSO 2 , or NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- Embodiment 32 The compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31, R 8 is H, OH, or CH 3 .
- Embodiment 33 The compound of embodiment 32, wherein R 8 is OH.
- Embodiment 34 The compound of embodiment 32, wherein R 8 is H.
- Embodiment 35 A compound, which is:
- Embodiment 36 A compound which is optionally substituted 9-methoxy-1H-imidazo [4, 5-c] quinolin-4-amine.
- Embodiment 37 A compound which is optionally substituted 9-methoxy-2H-pyrazolo [3, 4-c] quinolin-4-amine.
- Embodiment 38 The compound of embodiment 36, which is optionally substituted 1- (4-amino-2- (ethoxymethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -1-isobutyl-9-methoxy-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 1- (4-amino-9-methoxy-2- (2-methoxyethyl) -1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 1- (4-amino-2- (2-hydroxyethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 4- ( (4-amino
- Embodiment 39 The compound of embodiment 37 which is optionally substituted 4-amino-2H-pyrazolo [3, 4-c] quinolin-9-ol or a salt thereof; optionally substituted 4-amino-2-isopentyl-2H-pyrazolo [3, 4-c] quinolin-9-ol or a salt thereof; optionally substituted 2-isopentyl-9- (isopentyloxy) -2H-pyrazolo [3, 4-c] quinolin-4-amine or a salt thereof; or optionally substituted 2-butyl-9- (isopentyloxy) -2H-pyrazolo [3, 4-c] quinolin-4-amine or a salt thereof.
- Embodiment 40 A method of treating viral infection, cancer, or an allergic disease, comprising administering a compound according to embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 37, 38, or 39, to a mammal in need thereof.
- Embodiment 41 Use of a compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39, in the manufacture of a medicament for the treatment of viral infection, cancer, or an allergic disease.
- Embodiment 42 The method of embodiment 40 or use of embodiment 41, wherein the viral infection comprises HCV infection.
- Embodiment 43 A dosage form suitable for administration to a mammal, comprising a compound of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39.
- NMR spectra and 13 C-NMR were recorded on a Varian Mercury-VX400 instrument operating at 400 MHZ.
- NMR spectra were obtained as CDCl 3 solutions (reported in ppm) , using chloroform as the reference standard (7.27 ppm for the proton and 77.00 ppm for carbon) , CD 3 OD (3.4 and 4.8 ppm for the protons and 49.3 ppm for carbon) , DMSO-d 6 (2.49 ppm for proton) , or internally tetramethylsilane (0.00 ppm) when appropriate.
- Other NMR solvents were used as needed.
- Step 1 Synthesis of 1- [ (5-Methoxy-3-nitro-4-quinolyl) amino] -2-methyl-propan-2-ol
- Step 2 Synthesis of 1- [ (3-Amino-5-methoxy-4-quinolyl) amino] -2-methyl-propan-2-ol
- Step 3 Synthesis of 1- [2- (Ethoxymethyl) -9-methoxy-imidazo [4, 5-c] quinolin-1-yl] -2-methyl-propan-2-ol
- Step 4 Synthesis of 1- [2- (Ethoxymethyl) -9-methoxy-5-oxido-imidazo [4, 5-c] quinolin-5-ium-1-yl] -2-methyl-propan-2-ol
- Step 5 Synthesis of 1- [4-Amino-2- (ethoxymethyl) -9-methoxy-imidazo [4, 5-c] quinolin-1-yl] -2-methyl-propan-2-ol
- Step 1 Synthesis of 2- (Ethoxymethyl) -1-isobutyl-9-methoxy-imidazo [4, 5-c] quinoline
- Step 2 2- (Ethoxymethyl) -1-isobutyl-9-methoxy-5-oxido-imidazo [4, 5-c] quinolin-5-ium
- Step 5 Synthesis of 2- (Ethoxymethyl) -9-isopentyloxy-1H-imidazo [4, 5-c] quinolin-4-amine
- Step 1 Synthesis of 1- [ (4-Amino-3-nitro-5-quinolyl) oxy] propan-2-one
- Step 2 Synthesis of 1- [ (3, 4-Diamino-5-quinolyl) oxy] propan-2-ol
- Step 3 Synthesis of 1- [ [2- (Ethoxymethyl) -1H-imidazo [4, 5-c] quinolin-9-yl] oxy] propan-2-ol
- Step 4 Synthesis of 1- [ [2- (Ethoxymethyl) -5-oxido-1H-imidazo [4, 5-c] quinolin-5-ium-9-yl] oxy] propan-2-ol
- Step 5 Synthesis of 1- [ [4-Amino-2- (ethoxymethyl) -1H-imidazo [4, 5-c] quinolin-9-yl] oxy] -propan-2-ol
- Step 1 Synthesis of 4- [ [2- (2-Methoxyethyl) -1H-imidazo [4, 5-c] quinolin-9-yl] oxy] -2-methyl-butan-2-ol
- Step 2 Synthesis of 4- [ [2- (2-Methoxyethyl) -5-oxido-1H-imidazo [4, 5-c] quinolin-5-ium-9-yl] oxy] -2-methyl-butan-2-ol
- Step 3 Synthesis of 4- [ [4-Amino-2- (2-methoxyethyl) -1H-imidazo [4, 5-c] quinolin-9-yl] oxy] -2-methyl-butan-2-ol
- Step 1 Synthesis of 4- (methylamino) -3-nitro-quinolin-5-ol
- Step 2 Synthesis of 2-methyl-4- [ [4- (methylamino) -3-nitro-5-quinolyl] oxy] butan-2-ol
- Step 3 Synthesis of 4- [ [3-Amino-4- (methylamino) -5-quinolyl] oxy] -2-methyl-butan-2-ol
- Step 4 Synthesis of 4- [2- (ethoxymethyl) -1-methyl-imidazo [4, 5-c] quinolin-9-yl] oxy-2-methyl-butan-2 -ol
- Step 5 Synthesis of 4- [2- (Ethoxymethyl) -1-methyl-5-oxido-imidazo [4, 5-c] quinolin-5-ium-9-yl] oxy-2-methyl-butan-2-ol
- Step 6 Synthesis of 4- [4-Amino-2- (ethoxymethyl) -1-methyl-imidazo [4, 5-c] quinolin-9-yl] oxy-2-methyl-butan-2-ol
- Step 3 Synthesis of 4- [2- (Ethoxymethyl) -1-isobutyl-imidazo [4, 5-c] quinolin-9-yl] oxy-2-methyl-butan-2-ol
- Step 4 Synthesis of 4- [2- (Ethoxymethyl) -1-isobutyl-5-oxido-imidazo [4, 5-c] quinolin-5-ium-9-yl] oxy-2-methyl-butan-2-ol
- Step 5 Synthesis of 4- [4-Amino-2- (ethoxymethyl) -1-isobutyl-imidazo [4, 5-c] quinolin-9-yl] oxy-2-methyl-butan-2-ol
- Step 1 Synthesis of 2-methoxy-6- [ [ (E) -2-nitrovinyl] amino] benzoic acid
- Step 2 Synthesis of N 4 -isobutyl-5-methoxy-quinoline-3, 4-diamine
- Step 1 Synthesis of 4- [ (4-amino-3-nitro-5-quinolyl) oxy] -2-methyl-butan-2-ol
- Step 2 Synthesis of 4- [ (3, 4-diamino-5-quinolyl) oxy] -2-methyl-butan-2-ol
- 3-Methoxypropanoyl chloride was prepared in the same way as intermediate 6 using the corresponding starting material of 3-methoxypropanoic acid in 84.9%yield as yellow oil.
- Acetonyl 4-methylbenzenesulfonate was prepared in a similar way as intermediate 8 using the corresponding starting material of 1-hydroxypropan-2-one in 25.31%yield as a colorless oil.
- the compound functionality was tested for some of the compounds prepared by stimulation and determination of cytokine production in PBMCs.
- Human PBMCs were prepared from buffy coat obtained from healthy volunteer donor by Ficoll centrifugation and were adjusted to the final cell concentration to 1x10 6 cells/mL.
- PBMCs were plated in a 96-well plate in 100 ⁇ l of RPMI 1640 complete medium (cat no. 31800-022, GIBCO by Life Technologies, Grand Island, NY, USA) supplemented with 10%fetal bovine serum, the tested compound was first dissolved in DMSO and further diluted in PBS and RPMI 1640 medium to the final concentration of 20 ⁇ M (corresponding to 6.28 ⁇ g/mL) , then 3-fold serially dilution was made in a 96-well round-bottom plate. 100 ⁇ l diluted compound was added to the same volume of 1 ⁇ 10 5 PBMCs plate and cultured for 20-22 hours at 37°C in a humidified atmosphere of 5%CO 2 . The supernatant was collected for human IFN- ⁇ , IL12 (p70) and IL-6 analysis by ELISA assay according to the manufacturer’s instructions (Mabtech AB, Sweden) . Resiquimod was used as a positive control.
- RPMI 1640 complete medium catalog no
- Table 2 lists the testing results on the evaluation of cytokine production for most of the compounds prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (43)
- A compound represented by a formula:wherein a dashed line represents the presence or absence of a bond;A 1 is CR 1, NR 1A, or N;A 2 is CR 2, NR 2A, O, or S;B 1 is CR 5 or N;B 2 is CR 6 or N;B 3 is CR 7 or N;R 1 and R 2 are independently F, Cl, Br, I, NO 2, CN, R a, -OR a, -NR aR b, -NHCOR a, -NHSO 2R a, -OCOR a, or -SO 2R a;X is a bond, O, NR a, -CO-, -SO-, or -SO 2-, -CONR a, hydrocarbonyl, and R 3 is H or C 1-30 organyl; or X-R 3 is F or Cl;R 1A, R 2A, R 4, R a, and R b are independently H or C 1-30 organyl;R 5, R 6, and R 7 are independently F, Cl, Br, I, NO 2, CN, R a, -OR a, -NR aR b, -NHCOR a, -NHSO 2R a, -OCOR a, -SO 2R a, -SO 2NHR a, or -X 1- (C mH 2mO 0-1) -Z- (C nH 2n+1) , - (C mH 2mO 0-1) -Z- (C nH 2n+1) , wherein R 5 and R 6 or R 6 and R 7 can be optionally linked to form a ring;wherein X 1 is a bond, O, NR a, -CO-, -SO-, or -SO 2-;Z is a bond, O, NHSO 2, or NHCO;m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; andn is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- The compound of claim 1, 2 or 3, wherein R 1 or R 1A is C 1-12 optionally substituted alkyl.
- The compound of claim 4, wherein R 1 or R 1A is -C rH 2r+1O, or an ester thereof, wherein r is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- The compound of claim 5, wherein R 1 or R 1A is -C 3H 7O.
- The compound of claim 6, wherein R 1 or R 1A is -CH 2OCH 2CH 3.
- The compound of any one claims 1 to 7, wherein R 2 or R 2A is H or C 1-12 optionally substituted alkyl.
- The compound of claim 8, wherein R 2 or R 2A is C 1-6 alkyl, or -C yH 2y+1O or an ester thereof, wherein y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- The compound of claim 9, wherein R 2 or R 2A is CH 3.
- The compound of claim 8, wherein R 2 or R 2A is H.
- The compound of claim 8, wherein R 2 or R 2A is C 4H 9.
- The compound of any one of claims 1 to 12, wherein R 3 is C 1-30 optionally substituted alkyl.
- The compound of claim 13, wherein R 3 is C 1-10 alkyl, or -C wH 2w+1O or an ester thereof, wherein w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- The compound of any one of claims 1 to 13, wherein R 3 is - (C tH 2tO 0-1) -Ht, wherein t is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and Ht is optionally substituted C 3-6 heterocyclyl.
- The compound of any one of claims 1 to 13, wherein R 3 is - (C uH 2uO 0-1) -Z- (C vH 2v+1) , wherein Z is a bond, O, NHSO 2, or NHCO, u is 0, 1, 2, 3, 4, 5, or 6, and v is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- The compound of any one of claims 1 to 13, wherein R 3 is - (C uH 2uO 0-1) -NR aR b, and u is 1, 2, 3, 4, 5, or 6, wherein R a and R b are independently H or C 1-6 alkyl.
- The compound of claim 14, wherein R 3 is C 5H 11O.
- The compound of claim 18, wherein R 3 is -CH 2-CH 2-CH (CH 3) 2OH.
- The compound of claim 17, wherein R 3 is -CH 2-CH 2-CH 2-NH 2.
- The compound of any one of claims 1 to 20, wherein R 4 is H or C 1-6 alkyl.
- The compound of claim 21, wherein R 4 is H.
- The compound of any one of claims 1 to 22, wherein R 5 is R a, F, Cl, -CO 2R a, -CONR aR b, CN, -OR a, -NR aR b, -OCOR a, or -SO 2R a, -SO 2NHR a, wherein R a and R b are independently H or C 1-6 alkyl.
- The compound of claim 23, wherein R 5 is H.
- The compound of any one of claims 1 to 20, wherein R 5 is - (C mH 2mO 0-1) -Z- (C nH 2n+1) , wherein Z is a bond, O, NHSO 2, or NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25.
- The compound of any one of claims 1 to 25, wherein R 6 is R a, F, Cl, -CO 2R a, -CONR aR b, CN, -OR a, -NR aR b, -OCOR a, or -SO 2R a, -SO 2NHR a, wherein R a and R b are independently H or C 1-6 alkyl.
- The compound of claim 26, wherein R 6 is H.
- The compound of any one of claims 1 to 25, wherein R 6 is - (C mH 2mO 0-1) -Z- (C nH 2n+1) , wherein Z is a bond, O, NHSO 2, or NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- The compound of any one of claims 1 to 28, wherein R 7 is R a, F, Cl, -CO 2R a, -CONR aR b, CN, -OR a, -NR aR b, -OCOR a, or -SO 2R a, -SO 2NHR a, wherein R a and R b are independently H or C 1-6 alkyl.
- The compound of claim 29, wherein R 7 is H.
- The compound of any one of claims 1 to 28, wherein R 7 is - (C mH 2mO 0-1) -Z- (C nH 2n+1) , wherein Z is a bond, O, NHSO 2, or NHCO, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23.
- The compound of any one of claims 1 to 31, R 8 is H, OH, or CH 3.
- The compound of claim 32, wherein R 8 is OH.
- The compound of claim 32, wherein R 8 is H.
- A compound which is optionally substituted 9-methoxy-1H-imidazo [4, 5-c] quinolin-4-amine.
- A compound which is optionally substituted 9-methoxy-2H-pyrazolo [3, 4-c] quinolin-4-amine.
- The compound of claim 36, which is optionally substituted 1- (4-amino-2- (ethoxymethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -1-isobutyl-9-methoxy-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 1- (4-amino-9-methoxy-2- (2-methoxyethyl) -1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 1- (4-amino-2- (2-hydroxyethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylpropan-2-ol or a salt thereof; optionally substituted 4- ( (4-amino-2- (ethoxymethyl) -1H-imidazo [4, 5-c] quinolin-9-yl) oxy) -2-methylbutan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -9- (isopentyloxy) -1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 4- ( (4-amino-2- (ethoxymethyl) -1H-imidazo [4, 5-c] quinolin-9-yl) oxy) butan-2-ol or a salt thereof; optionally substituted 1- ( (4-amino-2- (ethoxymethyl) -1H-imidazo [4, 5-c] quinolin-9-yl) oxy) propan-2-ol or a salt thereof; optionally substituted 4- ( (4-amino-2- (2-methoxyethyl) -1H- imidazo [4, 5-c] quinolin-9-yl) oxy) -2-methylbutan-2-ol or a salt thereof; optionally substituted 4- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) -2-methylbutan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -9- (2-isopropoxyethoxy) -1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 4- ( (4-amino-2- (ethoxymethyl) -1-isobutyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) -2-methylbutan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -1- (2-isopropoxyethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optinoally substituted 4- (4-amino-2- (ethoxymethyl) -9-methoxy-1H-imidazo [4, 5-c] quinolin-1-yl) -2-methylbutan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -9-isobutoxy-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 2- (ethoxymethyl) -9- (2-isopropoxyethoxy) -1-methyl-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 2- (ethoxymethyl) -9- (isopentyloxy) -1-methyl-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 2- (ethoxymethyl) -9-isobutoxy-1-methyl-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted N- (3- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) propyl) methanesulfonamide or a salt thereof; optionally substituted N- (2- (2- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) ethoxy) ethyl) -methanesulfonamide or a salt thereof; optionally substituted N- (3- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) propyl) acetamide or a salt thereof; optionally substituted N- (4- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) butyl) methanesulfonamide or a salt thereof; optionally substituted N- (3- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) propyl) stearamide or a salt thereof; optionally substituted N- (4- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) butyl) acetamide or a salt thereof; optionally substituted N- (4- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) butyl) -stearamide or a salt thereof; optionally substituted 2- (ethoxymethyl) -1-methyl-9- (2-morpholinoethoxy) -1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 2- (ethoxymethyl) -1-methyl-9- ( (tetrahydrofuran-3-yl) oxy) -1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 2- (ethoxymethyl) -1-methyl-9- (pyrrolidin-3-yloxy) -1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 2- (ethoxymethyl) -1-methyl-9- (piperidin-4-yloxy) -1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted N- (3- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) propyl) palmitamide or a salt thereof; optionally substituted N- (4- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) butyl) palmitamide or a salt thereof; optionally substituted 9- (3-aminopropoxy) -2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 2- (ethoxymethyl) -9-isopropoxy-1-methyl-1H-imidazo [4, 5-c] quinolin-4-amine or a salt thereof; optionally substituted 1- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) -2-methylpropan-2-ol or a salt thereof; optionally substituted 2- (ethoxymethyl) -3, 4-dihydro-5-oxa-1, 2a, 9- triazanaphtho [2, 1, 8-cde] azulen-10-amine or a salt thereof; optionally substituted (R) -2- (10-amino-2- (ethoxymethyl) -3, 4-dihydro-5-oxa-1, 2a, 9-triazanaphtho [2, 1, 8-cde] azulen-3-yl) propan-2-ol or a salt thereof; optionally substituted (S) -2- (10-amino-2- (ethoxymethyl) -3, 4-dihydro-5-oxa-1, 2a, 9-triazanaphtho [2, 1, 8-cde] azulen-3-yl) propan-2-ol or a salt thereof; optionally substituted (S) -2-amino-12- (ethoxymethyl) -6-methyl-6, 7-dihydro-5H-3, 4- (azenometheno) [1, 5] oxazocino [4, 3, 2-de] quinolin-6-ol or a salt thereof; optionally substituted (R) -2-amino-12- (ethoxymethyl) -6-methyl-6, 7-dihydro-5H-3, 4- (azenometheno) [1, 5] oxazocino [4, 3, 2-de] quinolin-6-ol or a salt thereof; optionally substituted (R) -2-amino-12- (ethoxymethyl) -6, 7-dihydro-5H-3, 4- (azenometheno) [1, 5] oxazocino [4, 3, 2-de] quinolin-6-ol or a salt thereof; optionally substituted (S) -2-amino-12- (ethoxymethyl) -6, 7-dihydro-5H-3, 4- (azenometheno) [1, 5] oxazocino- [4, 3, 2-de] quinolin-6-ol or a salt thereof; optionally substituted 2-amino-12- (ethoxymethyl) -5H-3, 4- (azenometheno) [1, 5] oxazocino [4, 3, 2-de] quinolin-6 (7H) -one or a salt thereof; or optionally substituted tert-butyl 4- ( (4-amino-2- (ethoxymethyl) -1-methyl-1H-imidazo [4, 5-c] quinolin-9-yl) oxy) piperidine-1-carboxylate or a salt thereof.
- The compound of claim 37 which is optionally substituted 4-amino-2H-pyrazolo [3, 4-c] quinolin-9-ol or a salt thereof; optionally substituted 4-amino-2-isopentyl-2H-pyrazolo [3, 4-c] quinolin-9-ol or a salt thereof; optionally substituted 2-isopentyl-9- (isopentyloxy) -2H-pyrazolo [3, 4-c] quinolin-4-amine or a salt thereof; or optionally substituted 2-butyl-9- (isopentyloxy) -2H-pyrazolo [3, 4-c] quinolin-4-amine or a salt thereof.
- A method of treating viral infection, cancer, or an allergic disease, comprising administering a compound according to any one of claims 1 to 39, to a mammal in need thereof.
- Use of a compound of any one of claims 1 to 39, in the manufacture of a medicament for the treatment of viral infection, cancer, or an allergic disease.
- The method of claim 40 or use of claim 41, wherein the viral infection comprises HCV infection.
- A dosage form suitable for administration to a mammal, comprising a compound of any one of claims 1 to 39.
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019012676A MX2019012676A (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives. |
JP2019558496A JP7179357B2 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
CN201880014574.0A CN110637018A (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
KR1020197033158A KR102541238B1 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
EP18792253.9A EP3615539B1 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
IL270219A IL270219B (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
RU2019138177A RU2019138177A (en) | 2017-04-27 | 2018-04-26 | 2-AMINOQUINOLINE DERIVATIVES |
BR112019022246-4A BR112019022246A2 (en) | 2017-04-27 | 2018-04-26 | compounds derived from 2-amino-quinoline and use thereof |
US16/608,581 US11053240B2 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
SG11201909325R SG11201909325RA (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
CA3061187A CA3061187A1 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
AU2018259831A AU2018259831B2 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
US17/315,156 US11834448B2 (en) | 2017-04-27 | 2021-05-07 | 2-amino-quinoline derivatives |
US17/315,162 US20210261549A1 (en) | 2017-04-27 | 2021-05-07 | 2-amino-quinoline derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710287322.2 | 2017-04-27 | ||
CN201710287322.2A CN108794467A (en) | 2017-04-27 | 2017-04-27 | 2- amino-quinoline derivatives |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/608,581 A-371-Of-International US11053240B2 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
US17/315,162 Continuation US20210261549A1 (en) | 2017-04-27 | 2021-05-07 | 2-amino-quinoline derivatives |
US17/315,156 Division US11834448B2 (en) | 2017-04-27 | 2021-05-07 | 2-amino-quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018196823A1 true WO2018196823A1 (en) | 2018-11-01 |
Family
ID=63918846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/084674 WO2018196823A1 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
Country Status (13)
Country | Link |
---|---|
US (3) | US11053240B2 (en) |
EP (1) | EP3615539B1 (en) |
JP (1) | JP7179357B2 (en) |
KR (1) | KR102541238B1 (en) |
CN (3) | CN118515666A (en) |
AU (1) | AU2018259831B2 (en) |
BR (1) | BR112019022246A2 (en) |
CA (1) | CA3061187A1 (en) |
IL (1) | IL270219B (en) |
MX (1) | MX2019012676A (en) |
RU (1) | RU2019138177A (en) |
SG (1) | SG11201909325RA (en) |
WO (1) | WO2018196823A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10660971B2 (en) | 2012-07-18 | 2020-05-26 | Birdie Biopharmaceuticals, Inc. | Compounds for targeted immunotherapy |
WO2020162705A1 (en) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same |
US10744206B2 (en) | 2014-01-10 | 2020-08-18 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
US11046781B2 (en) | 2016-01-07 | 2021-06-29 | Birdie Biopharmaceuticals, Inc. | Anti-HER2 combinations for treating tumors |
US11053240B2 (en) | 2017-04-27 | 2021-07-06 | Birdie Biopharmaceuticals, Inc. | 2-amino-quinoline derivatives |
US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
WO2021177679A1 (en) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
US11130812B2 (en) | 2014-09-01 | 2021-09-28 | Birdie Biopharmaceuticals, Inc. | Anti PD-L1 conjugates for treating tumors |
US11136397B2 (en) | 2016-01-07 | 2021-10-05 | Birdie Pharmaceuticals, Inc. | Anti-EGFR combinations for treating tumors |
US11220552B2 (en) | 2016-01-07 | 2022-01-11 | Birdie Biopharmaceuticals, Inc. | Anti-CD20 combinations for treating tumors |
WO2022031021A1 (en) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Mrna vaccine comprising adjuvant capable of kinetic control |
WO2022031011A1 (en) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Kinetically acting adjuvant ensemble |
WO2022031057A1 (en) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
US11279761B2 (en) | 2014-07-09 | 2022-03-22 | Birdie Biopharmaceuticals, Inc. | Anti-PD-L1 combinations for treating tumors |
US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
WO2022178437A1 (en) * | 2021-02-22 | 2022-08-25 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
US11976064B2 (en) | 2019-07-17 | 2024-05-07 | Pfizer Inc. | Toll-like receptor agonists |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
US12077539B2 (en) | 2021-03-22 | 2024-09-03 | Incyte Corporation | Imidazole and triazole KRAS inhibitors |
US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
JP2024537824A (en) | 2021-10-01 | 2024-10-16 | インサイト・コーポレイション | Pyrazoloquinoline KRAS inhibitors |
IL312114A (en) | 2021-10-14 | 2024-06-01 | Incyte Corp | Quinoline compounds as inhibitors of kras |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012143143A1 (en) * | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
WO2014060113A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
UA67760C2 (en) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
BRPI0012196B8 (en) | 1999-06-25 | 2021-05-25 | Genentech Inc | industrialized article |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
AU2006216669A1 (en) | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
WO2003094836A2 (en) | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US20040014779A1 (en) | 2001-11-16 | 2004-01-22 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and toll-like recptor pathways |
JP4493337B2 (en) | 2001-11-27 | 2010-06-30 | アナディス ファーマシューティカルズ インク | 3-β-D-ribofuranosyl thiazolo [4,5-d] pyrimidine nucleoside and uses thereof |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
DE10161767T1 (en) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotentiating compositions containing an anti-PD-L1 antibody |
EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
EP1590348A1 (en) | 2002-12-20 | 2005-11-02 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
ATE514713T1 (en) | 2002-12-23 | 2011-07-15 | Wyeth Llc | ANTIBODIES TO PD-1 AND THEIR USE |
AU2004204764A1 (en) | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Methods of treating lung diseases |
US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
WO2004071459A2 (en) | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
OA13310A (en) | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
CA2540598C (en) | 2003-10-03 | 2013-09-24 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
CA2540541C (en) * | 2003-10-03 | 2012-03-27 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
RU2426734C2 (en) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Pyrazolopyridines and analogues thereof |
CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
BR122018071808B8 (en) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugate |
US20050239735A1 (en) | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
TWI414525B (en) | 2004-03-26 | 2013-11-11 | Dainippon Sumitomo Pharma Co | 9-substituted-8-oxoadenine compound |
JP2008506683A (en) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ, リミテッド | Methods and compositions for inducing innate immune responses |
AU2005304771A1 (en) | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
AU2005321912B2 (en) | 2004-12-30 | 2012-04-05 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
AU2006216629A1 (en) | 2005-02-24 | 2006-08-31 | Janssen Pharmaceutica N.V. | Novel quinoline derivatives as potassium ion channel openers |
CN101155932A (en) | 2005-04-14 | 2008-04-02 | 默克专利有限公司 | Anti-egfr antibody therapy based on an increased copy number of the egfr gene in tumor tissues |
CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
KR101205064B1 (en) | 2005-04-26 | 2012-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Compositions and methods for cancer immunotherapy |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
TW201402124A (en) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 8-substituted benzoazepines as toll-like receptor modulators |
TWI382019B (en) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | Aminodiazepines as toll-like receptor modulators |
JP2009506790A (en) | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | EPH receptor antibody conjugated to toxin |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
US8951528B2 (en) | 2006-02-22 | 2015-02-10 | 3M Innovative Properties Company | Immune response modifier conjugates |
WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
RU2639543C9 (en) | 2006-10-27 | 2018-06-14 | Дженентек, Инк. | Antibodies and immunoconjugates and their applications |
NZ577440A (en) | 2006-12-21 | 2011-12-22 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TWI422594B (en) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr) |
EA019151B1 (en) | 2007-02-07 | 2014-01-30 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Conjugates of synthetic tlr agonists and uses thereof |
BRPI0811125A2 (en) | 2007-05-08 | 2017-05-09 | Astrazeneca Ab | imidazoquinolines with immunomodulatory properties |
RU2010107199A (en) | 2007-07-31 | 2011-09-10 | Дзе Джонс Хопкинс Юниверсити (Us) | CONJUGATE POLYPEPTIDE-NUCLEIC ACID FOR IMMUNOPROPHYLAXIS OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS |
GB0715428D0 (en) | 2007-08-08 | 2007-09-19 | Imp Innovations Ltd | Compositions and uses thereof |
EP2644192B1 (en) | 2007-09-28 | 2017-05-10 | Pfizer Inc | Cancer Cell Targeting Using Nanoparticles |
MX2010007699A (en) | 2008-01-15 | 2010-08-04 | Meda Ab | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives. |
EP2244738B1 (en) | 2008-01-25 | 2020-03-04 | Gavish-Galilee Bio Applications Ltd | Targeting of innate immune response to tumour site |
US20090202626A1 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
US8663643B2 (en) | 2008-03-18 | 2014-03-04 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
WO2010020590A1 (en) | 2008-08-20 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8 |
CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
EA021377B9 (en) | 2008-12-09 | 2015-09-30 | Джилид Сайэнс, Инк. | Modulators of toll-like receptors |
EP2427485B1 (en) | 2009-05-07 | 2016-12-07 | ImmunoCellular Therapeutics, Ltd. | Cd133 epitopes |
WO2010132622A2 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
US20110077263A1 (en) | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
DK3279215T3 (en) | 2009-11-24 | 2020-04-27 | Medimmune Ltd | TARGETED BINDING AGENTS B7-H1 |
WO2011084725A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
WO2011084726A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
WO2011130434A2 (en) | 2010-04-13 | 2011-10-20 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
US20110293701A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
AR082686A1 (en) | 2010-08-13 | 2012-12-26 | Baylor Res Inst | VACCINE ASSISTANTS DIRECTING ANTIBODY ADJUSTERS DIRECTLY TOWARDS ANTIGEN PRESENTING CELLS |
CN107970451A (en) | 2010-10-01 | 2018-05-01 | 帆德制药股份有限公司 | TLR activators and the treatment use of therapeutic alliance |
KR20140009275A (en) | 2010-12-09 | 2014-01-22 | 제넨테크, 인크. | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
PT2663555T (en) | 2011-01-12 | 2017-03-23 | Array Biopharma Inc | Substituted benzoazepines as toll-like receptor modulators |
RU2636029C2 (en) | 2011-02-01 | 2017-11-17 | Генмаб А/С | Human antibodies and conjugates of antibody-preparation against cd74 |
US20120231023A1 (en) | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells |
CN103608040B (en) | 2011-04-20 | 2017-03-01 | 米迪缪尼有限公司 | Antibody in conjunction with B7 H1 and PD 1 and other molecules |
AR086196A1 (en) * | 2011-04-21 | 2013-11-27 | Origenis Gmbh | DERIVATIVES OF PIRAZOLO [3,4-C] QUINOLINA, QUINASA INHIBITORS |
US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
PE20190262A1 (en) | 2011-08-01 | 2019-02-25 | Genentech Inc | METHODS FOR TREATING CANCER BY USE OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS |
CN103748084B (en) | 2011-08-11 | 2016-07-06 | 亨斯迈先进材料美国有限责任公司 | The method preparing benzoxazine compounds |
US9308253B2 (en) | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
EP2771294B1 (en) | 2011-10-25 | 2017-12-13 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
IN2014CN04251A (en) | 2011-11-09 | 2015-07-17 | Ascend Biopharmaceuticals Ltd | |
US9556167B2 (en) | 2012-05-02 | 2017-01-31 | Yale University | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) |
SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
CN112587658A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
JP6403166B2 (en) | 2012-08-03 | 2018-10-10 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Single antigen anti-PD-L1 and PD-L2 double-binding antibodies and methods of use thereof |
IL282082B (en) | 2012-08-23 | 2022-08-01 | Seagen Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
AU2014368898B2 (en) | 2013-12-20 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Combination therapy with neoantigen vaccine |
CN105899539B (en) | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | Compounds and compositions for immunotherapy |
AU2015279738A1 (en) | 2014-06-25 | 2016-12-22 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
EP4001311A1 (en) | 2014-07-09 | 2022-05-25 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
CN105440135A (en) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | Anti-PD-L1 conjugate for treating tumors |
CN112546230A (en) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | Combination therapeutic compositions and combination therapeutic methods for treating cancer |
CN105732635A (en) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | Toll-like receptor 7 agonist |
JP6141568B1 (en) | 2015-09-01 | 2017-06-07 | 大鵬薬品工業株式会社 | Novel pyrazolo [3,4-d] pyrimidine compound or salt thereof |
US10821127B2 (en) | 2015-11-09 | 2020-11-03 | Shaperon Inc. | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
CN106943596A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-CD 20 for treating tumour is combined |
CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-EGFR for treating tumour is combined |
CN115350279A (en) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | anti-HER 2 combinations for the treatment of tumors |
CN118515666A (en) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-Amino-quinoline derivatives |
JP7080501B2 (en) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Pharmaceutical composition |
JP2022501327A (en) | 2018-09-07 | 2022-01-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Imidazoquinoline compounds and their use |
JP2022516093A (en) | 2018-12-26 | 2022-02-24 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Combinations and methods of immunomodulators for the treatment of cancer |
US20220175762A1 (en) | 2019-03-15 | 2022-06-09 | Birdie Biopharmaceuticals, Inc. | Immune modulatory compositions and methods for treating cancers |
JP2023539625A (en) | 2020-08-26 | 2023-09-15 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Treatment of cancer with TLR agonists |
-
2017
- 2017-04-27 CN CN202410623331.4A patent/CN118515666A/en active Pending
- 2017-04-27 CN CN201710287322.2A patent/CN108794467A/en active Pending
-
2018
- 2018-04-26 CA CA3061187A patent/CA3061187A1/en active Pending
- 2018-04-26 EP EP18792253.9A patent/EP3615539B1/en active Active
- 2018-04-26 SG SG11201909325R patent/SG11201909325RA/en unknown
- 2018-04-26 IL IL270219A patent/IL270219B/en unknown
- 2018-04-26 US US16/608,581 patent/US11053240B2/en active Active
- 2018-04-26 JP JP2019558496A patent/JP7179357B2/en active Active
- 2018-04-26 RU RU2019138177A patent/RU2019138177A/en not_active Application Discontinuation
- 2018-04-26 WO PCT/CN2018/084674 patent/WO2018196823A1/en unknown
- 2018-04-26 CN CN201880014574.0A patent/CN110637018A/en active Pending
- 2018-04-26 AU AU2018259831A patent/AU2018259831B2/en active Active
- 2018-04-26 KR KR1020197033158A patent/KR102541238B1/en active IP Right Grant
- 2018-04-26 BR BR112019022246-4A patent/BR112019022246A2/en unknown
- 2018-04-26 MX MX2019012676A patent/MX2019012676A/en unknown
-
2021
- 2021-05-07 US US17/315,156 patent/US11834448B2/en active Active
- 2021-05-07 US US17/315,162 patent/US20210261549A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012143143A1 (en) * | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
WO2014060113A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP3615539A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10660971B2 (en) | 2012-07-18 | 2020-05-26 | Birdie Biopharmaceuticals, Inc. | Compounds for targeted immunotherapy |
US11786604B2 (en) | 2014-01-10 | 2023-10-17 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating HER2 positive tumors |
US10744206B2 (en) | 2014-01-10 | 2020-08-18 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
US10780180B2 (en) | 2014-01-10 | 2020-09-22 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
US11633494B2 (en) | 2014-01-10 | 2023-04-25 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
US11633495B2 (en) | 2014-01-10 | 2023-04-25 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for immunotherapy |
US11279761B2 (en) | 2014-07-09 | 2022-03-22 | Birdie Biopharmaceuticals, Inc. | Anti-PD-L1 combinations for treating tumors |
US11130812B2 (en) | 2014-09-01 | 2021-09-28 | Birdie Biopharmaceuticals, Inc. | Anti PD-L1 conjugates for treating tumors |
US11046781B2 (en) | 2016-01-07 | 2021-06-29 | Birdie Biopharmaceuticals, Inc. | Anti-HER2 combinations for treating tumors |
US11702476B2 (en) | 2016-01-07 | 2023-07-18 | Birdie Biopharmaceuticals, Inc. | Anti-EGFR combinations for treating tumors |
US11136397B2 (en) | 2016-01-07 | 2021-10-05 | Birdie Pharmaceuticals, Inc. | Anti-EGFR combinations for treating tumors |
US11220552B2 (en) | 2016-01-07 | 2022-01-11 | Birdie Biopharmaceuticals, Inc. | Anti-CD20 combinations for treating tumors |
US11547761B1 (en) | 2016-07-07 | 2023-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
US11053240B2 (en) | 2017-04-27 | 2021-07-06 | Birdie Biopharmaceuticals, Inc. | 2-amino-quinoline derivatives |
US11834448B2 (en) | 2017-04-27 | 2023-12-05 | Birdie Biopharmaceuticals, Inc. | 2-amino-quinoline derivatives |
US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
WO2020162705A1 (en) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same |
US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
US11976064B2 (en) | 2019-07-17 | 2024-05-07 | Pfizer Inc. | Toll-like receptor agonists |
WO2021177679A1 (en) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
WO2022031057A1 (en) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
WO2022031011A1 (en) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Kinetically acting adjuvant ensemble |
WO2022031021A1 (en) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Mrna vaccine comprising adjuvant capable of kinetic control |
WO2022178437A1 (en) * | 2021-02-22 | 2022-08-25 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
Also Published As
Publication number | Publication date |
---|---|
EP3615539B1 (en) | 2023-08-09 |
EP3615539A1 (en) | 2020-03-04 |
KR20190141174A (en) | 2019-12-23 |
BR112019022246A2 (en) | 2020-08-11 |
JP2020517711A (en) | 2020-06-18 |
CN108794467A (en) | 2018-11-13 |
KR102541238B1 (en) | 2023-06-08 |
US20210261549A1 (en) | 2021-08-26 |
US20210261548A1 (en) | 2021-08-26 |
AU2018259831A1 (en) | 2019-10-31 |
CN118515666A (en) | 2024-08-20 |
MX2019012676A (en) | 2020-02-05 |
IL270219B (en) | 2022-09-01 |
JP7179357B2 (en) | 2022-11-29 |
IL270219A (en) | 2019-12-31 |
US20200055851A1 (en) | 2020-02-20 |
CN110637018A (en) | 2019-12-31 |
US11053240B2 (en) | 2021-07-06 |
RU2019138177A3 (en) | 2021-05-27 |
AU2018259831B2 (en) | 2022-06-16 |
CA3061187A1 (en) | 2018-11-01 |
RU2019138177A (en) | 2021-05-27 |
EP3615539A4 (en) | 2020-08-19 |
SG11201909325RA (en) | 2019-11-28 |
US11834448B2 (en) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018259831B2 (en) | 2-amino-quinoline derivatives | |
JP6893501B2 (en) | Sulfinylphenyl or sulfonimideylphenyl benzazepine | |
US10882876B2 (en) | Pegylated imidazoquinolines as TLR7 and TLR8 agonists | |
JP6367366B2 (en) | 4-amino-imidazoquinoline compounds | |
AU2006242920A1 (en) | 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C | |
EA029926B1 (en) | 1,2-DISUBSTITUTED 4-AMINO-IMIDAZOQUINOLINES, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF AS Toll-LIKE RECEPTORS 7 (EMBODIMENTS) | |
JP6831324B2 (en) | Certain protein kinase inhibitors | |
US10954239B2 (en) | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | |
WO2023030335A1 (en) | Compound as tyk2/jak1 pseudokinase domain inhibitor, and synthesis and use methods | |
US11453688B2 (en) | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | |
CN114409653A (en) | Bridged ring pyrimidine-fused ring compound and application thereof | |
KR20220150356A (en) | Therapeutic agents and conjugates thereof | |
US12122772B2 (en) | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | |
CN118201933A (en) | Tri-fused ring compounds, preparation method and application thereof | |
TW202334097A (en) | Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18792253 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3061187 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019558496 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018259831 Country of ref document: AU Date of ref document: 20180426 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019022246 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20197033158 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018792253 Country of ref document: EP Effective date: 20191127 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112019022246 Country of ref document: BR Free format text: 1) APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE CN 201710287322.2 DE 27/04/2017 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA (DEPOSITANTE(S), INVENTOR(ES), NUMERO DE REGISTRO, DATA DE DEPOSITO E TITULO), CONFORME O PARAGRAFO UNICO DO ART. 25 DA RESOLUCAO 77/2013, UMA VEZ QUE NAO FOI POSSIVEL DETERMINAR O(S) TITULAR(ES) DA CITADA PRIORIDADE, NEM SEUS INVENTORES, INFORMACAO NECESSARIA PARA O EXAME. 2) REAPRESENTAR, EM ATE 60 (SESSENTA) DIAS, AS REIVINDICACOES ENVIADAS NA PETICAO NO 870190107606 DE 23/10/2019 CONTENDO A PAGINA 15, OU, CONFIRMAR SER UM ERRO DE PAGINACAO E RE-ENVIAR O CONTEUDO COM PAGINACAO CORRETA UMA VE |
|
ENP | Entry into the national phase |
Ref document number: 112019022246 Country of ref document: BR Kind code of ref document: A2 Effective date: 20191023 |